Covered recipient · General Payments record
HEIDI A MCKEAN
Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2020 · Entire year
$67.75
1 record · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2020 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $67.75 | 1 |
By paying entity
PY2020 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Daiichi Sankyo Inc. | $67.75 | 1 |
Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
HEIDI A MCKEAN
NPI 1992714281 · CMS profile ID 419958
Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology
SIOUX FALLS, SD
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1992714281?year=2020&recipient=provider#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- HEIDI A MCKEAN, NPI 1992714281, CMS profile ID 419958. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1992714281?year=2020&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
- APA 7
- IndustryPayments. (2026). HEIDI A MCKEAN, NPI 1992714281, CMS profile ID 419958. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1992714281?year=2020&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
- Bluebook
- HEIDI A MCKEAN, NPI 1992714281, CMS profile ID 419958, IndustryPayments, General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019. https://industrypayments.org/provider/npi-1992714281?year=2020&recipient=provider#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2020
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2020 · Physicians and non-physician practitioners · CMS publication 2026-06-30
1 matching record · $67.75 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 1–1 of 1.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| Daiichi Sankyo Inc. | $67.75 | 02/25/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 739474859 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2025
Source files and profile matching
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Principal investigator | $621,755.28 | 64 |
| PY2024 | Principal investigator | $670,932.23 | 24 |
| PY2023 | Principal investigator | $188,869.75 | 16 |
| PY2022 | Principal investigator | $191,521.33 | 17 |
| PY2021 | Principal investigator | $269,453.84 | 10 |
| PY2020 | Principal investigator | $41,893.57 | 9 |
| PY2019 | Principal investigator | $58,617.55 | 8 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
64 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | Merck Sharp & Dohme LLC | $733.80 | 12/31/2025 | Covered Recipient Teaching Hospital Avera Mckennan | A Phase 2a Study with Safety Run-in to Evaluate the Safety, Tolerability, and Preliminary Efficacy of FF-10832 Monotherapy or in Combination with Pembrolizumab in Patients with Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1232932483 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $509.10 | 12/17/2025 | Non-covered Recipient Entity Avera Medical Group Oncology And Hematology Public Health Service Outpatient | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220642580 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $139.92 | 12/17/2025 | Non-covered Recipient Entity Avera Medical Group Oncology And Hematology Public Health Service Outpatient | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220642582 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $539.46 | 12/17/2025 | Non-covered Recipient Entity Avera Medical Group Oncology And Hematology Public Health Service Outpatient | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220642584 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $292.00 | 12/17/2025 | Non-covered Recipient Entity Avera Medical Group Oncology And Hematology Public Health Service Outpatient | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220642586 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $244.28 | 12/17/2025 | Non-covered Recipient Entity Avera Medical Group Oncology And Hematology Public Health Service Outpatient | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220642588 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $5.68 | 12/17/2025 | Non-covered Recipient Entity Avera Medical Group Oncology And Hematology Public Health Service Outpatient | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220642590 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $143.00 | 12/17/2025 | Non-covered Recipient Entity Avera Medical Group Oncology And Hematology Public Health Service Outpatient | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220642592 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $30.66 | 12/17/2025 | Non-covered Recipient Entity Avera Medical Group Oncology And Hematology Public Health Service Outpatient | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220642594 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $1,500.00 | 12/17/2025 | Covered Recipient Teaching Hospital AVERA MCKENNAN | A PHASE 1/2, FIRST-IN-HUMAN, OPEN LABEL, DOSE ESCALATION STUDY OF MVC-101, AN EGFR X CD3 CONDITIONAL BISPECIFIC REDIRECTED ACTIVATION (COBRATM) PROTEIN IN PATIENTS WITH UNRESECTABLE LOCALLY ADVANCED OR METASTATIC CANCER | No dispute reported | 06/30/2026 | 1223263838 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $800.00 | 12/17/2025 | Covered Recipient Teaching Hospital AVERA MCKENNAN | A PHASE 1/2, FIRST-IN-HUMAN, OPEN LABEL, DOSE ESCALATION STUDY OF MVC-101, AN EGFR X CD3 CONDITIONAL BISPECIFIC REDIRECTED ACTIVATION (COBRATM) PROTEIN IN PATIENTS WITH UNRESECTABLE LOCALLY ADVANCED OR METASTATIC CANCER | No dispute reported | 06/30/2026 | 1223263840 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $2,000.00 | 12/17/2025 | Covered Recipient Teaching Hospital AVERA MCKENNAN | A PHASE 1/2, FIRST-IN-HUMAN, OPEN LABEL, DOSE ESCALATION STUDY OF MVC-101, AN EGFR X CD3 CONDITIONAL BISPECIFIC REDIRECTED ACTIVATION (COBRATM) PROTEIN IN PATIENTS WITH UNRESECTABLE LOCALLY ADVANCED OR METASTATIC CANCER | No dispute reported | 06/30/2026 | 1223263842 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $56.70 | 12/17/2025 | Covered Recipient Teaching Hospital AVERA MCKENNAN | A PHASE 1/2, FIRST-IN-HUMAN, OPEN LABEL, DOSE ESCALATION STUDY OF MVC-101, AN EGFR X CD3 CONDITIONAL BISPECIFIC REDIRECTED ACTIVATION (COBRATM) PROTEIN IN PATIENTS WITH UNRESECTABLE LOCALLY ADVANCED OR METASTATIC CANCER | No dispute reported | 06/30/2026 | 1223263844 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $150.00 | 12/08/2025 | Non-covered Recipient Entity Avera Medical Group Oncology And Hematology Public Health Service Outpatient | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220642576 |
| Principal investigator 1 | ABBVIE INC. | $2,499.74 | 12/05/2025 | Covered Recipient Teaching Hospital AVERA MCKENNAN | Study to Assess Adverse Events and Change in Disease Activity in Previously Treated Adult Participants Receiving Intravenous (IV) ABBV-400 With Unresectable Metastatic Colorectal Cancer in Combination With IV Fluorouracil Folinic Acid and Bevacizumab | No dispute reported | 06/30/2026 | 1202404680 |
| Principal investigator 1 | ABBVIE INC. | $2,601.38 | 12/04/2025 | Covered Recipient Teaching Hospital AVERA MCKENNAN | Study to Assess Adverse Events and Change in Disease Activity in Previously Treated Adult Participants Receiving Intravenous (IV) ABBV-400 With Unresectable Metastatic Colorectal Cancer in Combination With IV Fluorouracil Folinic Acid and Bevacizumab | No dispute reported | 06/30/2026 | 1202404676 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $29.00 | 12/01/2025 | Non-covered Recipient Entity Avera Medical Group Oncology And Hematology Public Health Service Outpatient | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220642578 |
| Principal investigator 1 | ABBVIE INC. | $6,368.04 | 11/13/2025 | Covered Recipient Teaching Hospital AVERA MCKENNAN | Study to Assess Adverse Events and Change in Disease Activity in Previously Treated Adult Participants Receiving Intravenous (IV) ABBV-400 With Unresectable Metastatic Colorectal Cancer in Combination With IV Fluorouracil Folinic Acid and Bevacizumab | No dispute reported | 06/30/2026 | 1202404670 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $29.00 | 11/01/2025 | Non-covered Recipient Entity Avera Medical Group Oncology And Hematology Public Health Service Outpatient | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220642574 |
| Principal investigator 1 | ABBVIE INC. | $3,300.00 | 09/25/2025 | Covered Recipient Teaching Hospital AVERA MCKENNAN | Study to Assess Adverse Events and Change in Disease Activity in Previously Treated Adult Participants Receiving Intravenous (IV) ABBV-400 With Unresectable Metastatic Colorectal Cancer in Combination With IV Fluorouracil Folinic Acid and Bevacizumab | No dispute reported | 06/30/2026 | 1202404663 |
| Principal investigator 1 | ABBVIE INC. | $3,350.01 | 09/25/2025 | Covered Recipient Teaching Hospital AVERA MCKENNAN | Study to Assess Adverse Events and Change in Disease Activity in Previously Treated Adult Participants Receiving Intravenous (IV) ABBV-400 With Unresectable Metastatic Colorectal Cancer in Combination With IV Fluorouracil Folinic Acid and Bevacizumab | No dispute reported | 06/30/2026 | 1202404666 |
| Principal investigator 1 | PFIZER INC. | $7,969.40 | 09/22/2025 | Non-covered Recipient Entity Avera Cancer Institute | AN OPENLABEL RANDOMIZED PHASE 3 STUDY OF TUCATINIB IN COMBINATION WITH TRASTUZUMAB AND MFOLFOX6 VERSUS MFOLFOX6 GIVEN WITH OR WITHOUT EITHER CETUXIMAB OR BEVACIZUMAB AS FIRSTLINE TREATMENT FOR SUBJECTS WITH HER2 METASTATIC COLORECTAL CANCER | No dispute reported | 06/30/2026 | 1228717701 |
| Principal investigator 1 | PFIZER INC. | $10,940.00 | 09/22/2025 | Non-covered Recipient Entity Avera Cancer Institute | AN OPENLABEL RANDOMIZED PHASE 3 STUDY OF TUCATINIB IN COMBINATION WITH TRASTUZUMAB AND MFOLFOX6 VERSUS MFOLFOX6 GIVEN WITH OR WITHOUT EITHER CETUXIMAB OR BEVACIZUMAB AS FIRSTLINE TREATMENT FOR SUBJECTS WITH HER2 METASTATIC COLORECTAL CANCER | No dispute reported | 06/30/2026 | 1228717825 |
| Principal investigator 1 | PFIZER INC. | $32,997.51 | 09/22/2025 | Non-covered Recipient Entity Avera Cancer Institute | AN OPENLABEL RANDOMIZED PHASE 3 STUDY OF TUCATINIB IN COMBINATION WITH TRASTUZUMAB AND MFOLFOX6 VERSUS MFOLFOX6 GIVEN WITH OR WITHOUT EITHER CETUXIMAB OR BEVACIZUMAB AS FIRSTLINE TREATMENT FOR SUBJECTS WITH HER2 METASTATIC COLORECTAL CANCER | No dispute reported | 06/30/2026 | 1228717827 |
| Principal investigator 1 | PFIZER INC. | $7,969.40 | 09/19/2025 | Non-covered Recipient Entity Avera Cancer Institute | AN OPENLABEL RANDOMIZED PHASE 3 STUDY OF TUCATINIB IN COMBINATION WITH TRASTUZUMAB AND MFOLFOX6 VERSUS MFOLFOX6 GIVEN WITH OR WITHOUT EITHER CETUXIMAB OR BEVACIZUMAB AS FIRSTLINE TREATMENT FOR SUBJECTS WITH HER2 METASTATIC COLORECTAL CANCER | No dispute reported | 06/30/2026 | 1228716801 |
| Principal investigator 1 | PFIZER INC. | $10,940.00 | 09/19/2025 | Non-covered Recipient Entity Avera Cancer Institute | AN OPENLABEL RANDOMIZED PHASE 3 STUDY OF TUCATINIB IN COMBINATION WITH TRASTUZUMAB AND MFOLFOX6 VERSUS MFOLFOX6 GIVEN WITH OR WITHOUT EITHER CETUXIMAB OR BEVACIZUMAB AS FIRSTLINE TREATMENT FOR SUBJECTS WITH HER2 METASTATIC COLORECTAL CANCER | No dispute reported | 06/30/2026 | 1228716973 |
| Principal investigator 1 | PFIZER INC. | $32,997.51 | 09/19/2025 | Non-covered Recipient Entity Avera Cancer Institute | AN OPENLABEL RANDOMIZED PHASE 3 STUDY OF TUCATINIB IN COMBINATION WITH TRASTUZUMAB AND MFOLFOX6 VERSUS MFOLFOX6 GIVEN WITH OR WITHOUT EITHER CETUXIMAB OR BEVACIZUMAB AS FIRSTLINE TREATMENT FOR SUBJECTS WITH HER2 METASTATIC COLORECTAL CANCER | No dispute reported | 06/30/2026 | 1228716975 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $4,353.99 | 09/16/2025 | Non-covered Recipient Entity AVERA MCKENNAN | A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY OF PERIOPERATIVE DOSTARLIMAB M | No dispute reported | 06/30/2026 | 1192168263 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $9,820.20 | 08/13/2025 | Covered Recipient Teaching Hospital AVERA MCKENNAN | A PHASE 1/2, FIRST-IN-HUMAN, OPEN LABEL, DOSE ESCALATION STUDY OF MVC-101, AN EGFR X CD3 CONDITIONAL BISPECIFIC REDIRECTED ACTIVATION (COBRATM) PROTEIN IN PATIENTS WITH UNRESECTABLE LOCALLY ADVANCED OR METASTATIC CANCER | No dispute reported | 06/30/2026 | 1223263820 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $1,732.90 | 08/13/2025 | Covered Recipient Teaching Hospital AVERA MCKENNAN | A PHASE 1/2, FIRST-IN-HUMAN, OPEN LABEL, DOSE ESCALATION STUDY OF MVC-101, AN EGFR X CD3 CONDITIONAL BISPECIFIC REDIRECTED ACTIVATION (COBRATM) PROTEIN IN PATIENTS WITH UNRESECTABLE LOCALLY ADVANCED OR METASTATIC CANCER | No dispute reported | 06/30/2026 | 1223263822 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $1,500.00 | 07/24/2025 | Non-covered Recipient Entity AVERA MCKENNAN | A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY OF PERIOPERATIVE DOSTARLIMAB M | No dispute reported | 06/30/2026 | 1192165185 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $1,368.38 | 07/21/2025 | Non-covered Recipient Entity AVERA MCKENNAN | A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY OF PERIOPERATIVE DOSTARLIMAB M | No dispute reported | 06/30/2026 | 1192165181 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $11,215.04 | 07/21/2025 | Non-covered Recipient Entity AVERA MCKENNAN | A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY OF PERIOPERATIVE DOSTARLIMAB M | No dispute reported | 06/30/2026 | 1192168260 |
| Principal investigator 1 | ABBVIE INC. | $750.00 | 07/08/2025 | Covered Recipient Teaching Hospital AVERA MCKENNAN | A Randomized Trial Assessing Adverse Events and Disease Activity When Comparing Intravenously (IV) Infused ABBV-400 to Trifluridine and Tipiracil (LONSURF) Oral Tablets Plus IV Infused Bevacizumab in Adult Participants With c-Met Over-Expressed Refractory Metastatic Colorectal Cancer | No dispute reported | 06/30/2026 | 1202404659 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $6,660.98 | 06/13/2025 | Non-covered Recipient Entity AVERA MCKENNAN | A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY OF PERIOPERATIVE DOSTARLIMAB M | No dispute reported | 06/30/2026 | 1192168256 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $90,545.00 | 06/04/2025 | Covered Recipient Teaching Hospital AVERA MCKENNAN | A PHASE 1/2, FIRST-IN-HUMAN, OPEN LABEL, DOSE ESCALATION STUDY OF MVC-101, AN EGFR X CD3 CONDITIONAL BISPECIFIC REDIRECTED ACTIVATION (COBRATM) PROTEIN IN PATIENTS WITH UNRESECTABLE LOCALLY ADVANCED OR METASTATIC CANCER | No dispute reported | 06/30/2026 | 1223263814 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $1,551.00 | 06/04/2025 | Covered Recipient Teaching Hospital AVERA MCKENNAN | A PHASE 1/2, FIRST-IN-HUMAN, OPEN LABEL, DOSE ESCALATION STUDY OF MVC-101, AN EGFR X CD3 CONDITIONAL BISPECIFIC REDIRECTED ACTIVATION (COBRATM) PROTEIN IN PATIENTS WITH UNRESECTABLE LOCALLY ADVANCED OR METASTATIC CANCER | No dispute reported | 06/30/2026 | 1223263816 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $1,427.66 | 05/28/2025 | Non-covered Recipient Entity AVERA CANCER INSTITUTE AT SIOUX FALLS | A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY OF PERIOPERATIVE DOSTARLIMAB M | No dispute reported | 06/30/2026 | 1192168276 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $2,025.40 | 05/23/2025 | Covered Recipient Teaching Hospital AVERA MCKENNAN | A PHASE 1/2, FIRST-IN-HUMAN, OPEN LABEL, DOSE ESCALATION STUDY OF MVC-101, AN EGFR X CD3 CONDITIONAL BISPECIFIC REDIRECTED ACTIVATION (COBRATM) PROTEIN IN PATIENTS WITH UNRESECTABLE LOCALLY ADVANCED OR METASTATIC CANCER | No dispute reported | 06/30/2026 | 1223263812 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $11,530.59 | 05/14/2025 | Non-covered Recipient Entity AVERA MCKENNAN | A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY OF PERIOPERATIVE DOSTARLIMAB M | No dispute reported | 06/30/2026 | 1192165193 |
| Principal investigator 1 | Merck Sharp & Dohme LLC | $124,200.00 | 05/02/2025 | Covered Recipient Teaching Hospital Avera Mckennan | A Phase 2a Study with Safety Run-in to Evaluate the Safety, Tolerability, and Preliminary Efficacy of FF-10832 Monotherapy or in Combination with Pembrolizumab in Patients with Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1232932531 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $1,652.43 | 04/28/2025 | Non-covered Recipient Entity AVERA MCKENNAN | A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY OF PERIOPERATIVE DOSTARLIMAB M | No dispute reported | 06/30/2026 | 1192165189 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $3,208.53 | 04/28/2025 | Non-covered Recipient Entity AVERA MCKENNAN | A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY OF PERIOPERATIVE DOSTARLIMAB M | No dispute reported | 06/30/2026 | 1192168249 |
| Principal investigator 1 | PFIZER INC. | $10,940.00 | 04/16/2025 | Non-covered Recipient Entity Avera Cancer Institute | AN OPENLABEL RANDOMIZED PHASE 3 STUDY OF TUCATINIB IN COMBINATION WITH TRASTUZUMAB AND MFOLFOX6 VERSUS MFOLFOX6 GIVEN WITH OR WITHOUT EITHER CETUXIMAB OR BEVACIZUMAB AS FIRSTLINE TREATMENT FOR SUBJECTS WITH HER2 METASTATIC COLORECTAL CANCER | No dispute reported | 06/30/2026 | 1228754734 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $11,177.40 | 04/16/2025 | Covered Recipient Teaching Hospital AVERA MCKENNAN | A PHASE 1/2, FIRST-IN-HUMAN, OPEN LABEL, DOSE ESCALATION STUDY OF MVC-101, AN EGFR X CD3 CONDITIONAL BISPECIFIC REDIRECTED ACTIVATION (COBRATM) PROTEIN IN PATIENTS WITH UNRESECTABLE LOCALLY ADVANCED OR METASTATIC CANCER | No dispute reported | 06/30/2026 | 1223263810 |
| Principal investigator 1 | PFIZER INC. | $10,940.00 | 04/14/2025 | Non-covered Recipient Entity Avera Cancer Institute | AN OPENLABEL RANDOMIZED PHASE 3 STUDY OF TUCATINIB IN COMBINATION WITH TRASTUZUMAB AND MFOLFOX6 VERSUS MFOLFOX6 GIVEN WITH OR WITHOUT EITHER CETUXIMAB OR BEVACIZUMAB AS FIRSTLINE TREATMENT FOR SUBJECTS WITH HER2 METASTATIC COLORECTAL CANCER | No dispute reported | 06/30/2026 | 1228756519 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $9,274.86 | 04/09/2025 | Non-covered Recipient Entity AVERA MCKENNAN | A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY OF PERIOPERATIVE DOSTARLIMAB M | No dispute reported | 06/30/2026 | 1192168272 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $10,173.31 | 03/21/2025 | Non-covered Recipient Entity AVERA MCKENNAN | A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY OF PERIOPERATIVE DOSTARLIMAB M | No dispute reported | 06/30/2026 | 1192168267 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $7,234.30 | 03/21/2025 | Non-covered Recipient Entity AVERA MCKENNAN | A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY OF PERIOPERATIVE DOSTARLIMAB M | No dispute reported | 06/30/2026 | 1192168280 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $11,177.40 | 03/19/2025 | Covered Recipient Teaching Hospital AVERA MCKENNAN | A PHASE 1/2, FIRST-IN-HUMAN, OPEN LABEL, DOSE ESCALATION STUDY OF MVC-101, AN EGFR X CD3 CONDITIONAL BISPECIFIC REDIRECTED ACTIVATION (COBRATM) PROTEIN IN PATIENTS WITH UNRESECTABLE LOCALLY ADVANCED OR METASTATIC CANCER | No dispute reported | 06/30/2026 | 1223263798 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $8,671.00 | 03/19/2025 | Covered Recipient Teaching Hospital AVERA MCKENNAN | A PHASE 1/2, FIRST-IN-HUMAN, OPEN LABEL, DOSE ESCALATION STUDY OF MVC-101, AN EGFR X CD3 CONDITIONAL BISPECIFIC REDIRECTED ACTIVATION (COBRATM) PROTEIN IN PATIENTS WITH UNRESECTABLE LOCALLY ADVANCED OR METASTATIC CANCER | No dispute reported | 06/30/2026 | 1223263800 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $1,500.00 | 03/19/2025 | Covered Recipient Teaching Hospital AVERA MCKENNAN | A PHASE 1/2, FIRST-IN-HUMAN, OPEN LABEL, DOSE ESCALATION STUDY OF MVC-101, AN EGFR X CD3 CONDITIONAL BISPECIFIC REDIRECTED ACTIVATION (COBRATM) PROTEIN IN PATIENTS WITH UNRESECTABLE LOCALLY ADVANCED OR METASTATIC CANCER | No dispute reported | 06/30/2026 | 1223263802 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $1,050.00 | 03/19/2025 | Covered Recipient Teaching Hospital AVERA MCKENNAN | A PHASE 1/2, FIRST-IN-HUMAN, OPEN LABEL, DOSE ESCALATION STUDY OF MVC-101, AN EGFR X CD3 CONDITIONAL BISPECIFIC REDIRECTED ACTIVATION (COBRATM) PROTEIN IN PATIENTS WITH UNRESECTABLE LOCALLY ADVANCED OR METASTATIC CANCER | No dispute reported | 06/30/2026 | 1223263804 |
| Principal investigator 1 | ABBVIE INC. | $21,750.00 | 03/11/2025 | Covered Recipient Teaching Hospital AVERA MCKENNAN | M24-064 - A Randomized Trial Assessing Adverse Events and Disease Activity When Comparing Intravenously (IV) Infused ABBV-400 to Trifluridine and Tipiracil (LONSURF) Oral Tablets Plus IV Infused Bevacizumab in Adult Participants With c-Met Over-Expressed Refractory Metastatic Colorectal Cancer | No dispute reported | 06/30/2026 | 1202404655 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $5,000.00 | 02/17/2025 | Covered Recipient Teaching Hospital AVERA MCKENNAN | A PHASE 1, RANDOMIZED, OBSERVER-BLIND, PLACEBO-CONTROLLED, SAFETY, IMMUNOGENICITY, AND DOSE RANGING STUDY OF PURIFIED INACTIVATED ZIKA VIRUS VACCINE (PIZV) CANDIDATE IN FLAVIVIRUS NA?VE AND PRIMED HEALTHY ADULTS AGED 18 TO 49 YEARS | No dispute reported | 06/30/2026 | 1223263796 |
| Principal investigator 1 | PFIZER INC. | $32,997.51 | 02/04/2025 | Non-covered Recipient Entity Avera Cancer Institute | AN OPENLABEL RANDOMIZED PHASE 3 STUDY OF TUCATINIB IN COMBINATION WITH TRASTUZUMAB AND MFOLFOX6 VERSUS MFOLFOX6 GIVEN WITH OR WITHOUT EITHER CETUXIMAB OR BEVACIZUMAB AS FIRSTLINE TREATMENT FOR SUBJECTS WITH HER2 METASTATIC COLORECTAL CANCER | No dispute reported | 06/30/2026 | 1228754855 |
| Principal investigator 1 | PFIZER INC. | $32,997.51 | 02/03/2025 | Non-covered Recipient Entity Avera Cancer Institute | AN OPENLABEL RANDOMIZED PHASE 3 STUDY OF TUCATINIB IN COMBINATION WITH TRASTUZUMAB AND MFOLFOX6 VERSUS MFOLFOX6 GIVEN WITH OR WITHOUT EITHER CETUXIMAB OR BEVACIZUMAB AS FIRSTLINE TREATMENT FOR SUBJECTS WITH HER2 METASTATIC COLORECTAL CANCER | No dispute reported | 06/30/2026 | 1228719977 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $13,202.80 | 01/22/2025 | Covered Recipient Teaching Hospital AVERA MCKENNAN | A PHASE 1/2, FIRST-IN-HUMAN, OPEN LABEL, DOSE ESCALATION STUDY OF MVC-101, AN EGFR X CD3 CONDITIONAL BISPECIFIC REDIRECTED ACTIVATION (COBRATM) PROTEIN IN PATIENTS WITH UNRESECTABLE LOCALLY ADVANCED OR METASTATIC CANCER | No dispute reported | 06/30/2026 | 1223263786 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $10,127.00 | 01/22/2025 | Covered Recipient Teaching Hospital AVERA MCKENNAN | A PHASE 1/2, FIRST-IN-HUMAN, OPEN LABEL, DOSE ESCALATION STUDY OF MVC-101, AN EGFR X CD3 CONDITIONAL BISPECIFIC REDIRECTED ACTIVATION (COBRATM) PROTEIN IN PATIENTS WITH UNRESECTABLE LOCALLY ADVANCED OR METASTATIC CANCER | No dispute reported | 06/30/2026 | 1223263788 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $864.50 | 01/22/2025 | Covered Recipient Teaching Hospital AVERA MCKENNAN | A PHASE 1/2, FIRST-IN-HUMAN, OPEN LABEL, DOSE ESCALATION STUDY OF MVC-101, AN EGFR X CD3 CONDITIONAL BISPECIFIC REDIRECTED ACTIVATION (COBRATM) PROTEIN IN PATIENTS WITH UNRESECTABLE LOCALLY ADVANCED OR METASTATIC CANCER | No dispute reported | 06/30/2026 | 1223263790 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $5,000.00 | 01/17/2025 | Covered Recipient Teaching Hospital AVERA MCKENNAN | A PHASE 1, RANDOMIZED, OBSERVER-BLIND, PLACEBO-CONTROLLED, SAFETY, IMMUNOGENICITY, AND DOSE RANGING STUDY OF PURIFIED INACTIVATED ZIKA VIRUS VACCINE (PIZV) CANDIDATE IN FLAVIVIRUS NA?VE AND PRIMED HEALTHY ADULTS AGED 18 TO 49 YEARS | No dispute reported | 06/30/2026 | 1223263778 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $5,000.00 | 01/17/2025 | Covered Recipient Teaching Hospital AVERA MCKENNAN | A PHASE 1, RANDOMIZED, OBSERVER-BLIND, PLACEBO-CONTROLLED, SAFETY, IMMUNOGENICITY, AND DOSE RANGING STUDY OF PURIFIED INACTIVATED ZIKA VIRUS VACCINE (PIZV) CANDIDATE IN FLAVIVIRUS NA?VE AND PRIMED HEALTHY ADULTS AGED 18 TO 49 YEARS | No dispute reported | 06/30/2026 | 1223263780 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $5,000.00 | 01/17/2025 | Covered Recipient Teaching Hospital AVERA MCKENNAN | A PHASE 1, RANDOMIZED, OBSERVER-BLIND, PLACEBO-CONTROLLED, SAFETY, IMMUNOGENICITY, AND DOSE RANGING STUDY OF PURIFIED INACTIVATED ZIKA VIRUS VACCINE (PIZV) CANDIDATE IN FLAVIVIRUS NA?VE AND PRIMED HEALTHY ADULTS AGED 18 TO 49 YEARS | No dispute reported | 06/30/2026 | 1223263782 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $5,000.00 | 01/17/2025 | Covered Recipient Teaching Hospital AVERA MCKENNAN | A PHASE 1, RANDOMIZED, OBSERVER-BLIND, PLACEBO-CONTROLLED, SAFETY, IMMUNOGENICITY, AND DOSE RANGING STUDY OF PURIFIED INACTIVATED ZIKA VIRUS VACCINE (PIZV) CANDIDATE IN FLAVIVIRUS NA?VE AND PRIMED HEALTHY ADULTS AGED 18 TO 49 YEARS | No dispute reported | 06/30/2026 | 1223263784 |